Publications en collaboration avec des chercheurs de Universidade de Lisboa (17)

2024

  1. Anti-miR-873-5p improves alcohol-related liver disease by enhancing hepatic deacetylation via SIRT1

    JHEP Reports, Vol. 6, Núm. 1

2023

  1. Cirrhosis is associated with lower serological responses to COVID-19 vaccines in patients with chronic liver disease

    JHEP Reports, Vol. 5, Núm. 5

  2. Combined Inhibition of Smoothened and the DNA Damage Checkpoint WEE1 Exerts Antitumor Activity in Cholangiocarcinoma

    Molecular cancer therapeutics, Vol. 22, Núm. 3, pp. 343-356

  3. Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance

    Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480

  4. miR-21-5p promotes NASH-related hepatocarcinogenesis

    Liver International, Vol. 43, Núm. 10, pp. 2256-2274

2022

  1. Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

    Nature medicine, Vol. 28, Núm. 4, pp. 752-765

  2. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models

    Journal of Hepatology, Vol. 77, Núm. 1, pp. 177-190

2021

  1. Adiponectin, Leptin, and IGF-1 Are Useful Diagnostic and Stratification Biomarkers of NAFLD

    Frontiers in Medicine, Vol. 8

  2. Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity

    Cell Death and Disease, Vol. 12, Núm. 6

  3. Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer (British Journal of Cancer, (2020), 123, 7, (1047-1059), 10.1038/s41416-020-0987-3)

    British Journal of Cancer

  4. RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease

    Gut, Vol. 70, Núm. 12, pp. 2359-2372

2020

  1. A novel serum metabolomic profile for the differential diagnosis of distal cholangiocarcinoma and pancreatic ductal adenocarcinoma

    Cancers, Vol. 12, Núm. 6

  2. Current and novel therapeutic opportunities for systemic therapy in biliary cancer

    British Journal of Cancer, Vol. 123, Núm. 7, pp. 1047-1059

  3. Extracellular vesicles in non-alcoholic fatty liver disease: Key players in disease pathogenesis and promising biomarker tools

    NAFLD and NASH: Biomarkers in Detection, Diagnosis and Monitoring (Springer International Publishing), pp. 157-180

2019

  1. Diagnostic and prognostic biomarkers in cholangiocarcinoma

    Liver International, Vol. 39, Núm. S1, pp. 108-122

2018

  1. MiRNA-21 ablation protects against liver injury and necroptosis in cholestasis

    Cell Death and Differentiation, Vol. 25, Núm. 5, pp. 857-872

2012

  1. PLGA-based nanoparticles: An overview of biomedical applications

    Journal of Controlled Release, Vol. 161, Núm. 2, pp. 505-522